Navigation Links
Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
Date:5/22/2012

BOSTON, May 22, 2012 /PRNewswire/ -- Rhythm announced today the results of a Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis. The trial demonstrated that RM-131 greatly accelerates gastric emptying in patients with diabetic gastroparesis. The findings were presented at the Digestive Disease Week 2012 conference in San Diego.

The Phase 1b clinical trial was a randomized, double-blind, placebo-controlled, single-dose crossover study in 10 patients with type 2 diabetes, a history and symptoms of diabetic gastroparesis, and documentation of delayed gastric emptying. The primary objective of the study was to evaluate the pharmacodynamic profile of RM-131 administered as a single dose (100 mcg) to patients with diabetic gastroparesis. The trial also assessed safety and tolerability.

In the poster, "Randomized, Placebo-Controlled, Single-Dose, Crossover Study of the Effects of RM-131 in Type 2 Diabetics with Documented Delayed Gastric Emptying," Andrea Shin, M.D., a Mayo Clinic gastroenterology Fellow and study author, presented the following clinical data:

RM-131 is effective in accelerating gastric emptying in patients with type 2 diabetes and delayed gastric emptying.

Gastric emptying time was reduced by 66%.

The greatest improvement was observed in patients with the most abnormal gastric emptying.

RM-131 was generally well tolerated, with no serious adverse events

RM-131 was successfully designed to retain the pharmacodynamic properties of human ghrelin at lower and less frequent doses.


"We want to thank the Mayo Clinic for running this excellent clinical study," said Keith Gottesdiener, MD, CEO of Rhythm. "There is a great need for new treatments for diabetic gastroparesis, which afflicts patients with debilitating symptoms and causes frequent hospitalizations. These RM-131 results are encouraging and serve as the foundation for further clinical trials with RM-131 for the treatment of gastroparesis and other GI functional disorders."

About RM-131

RM-131 is a small-peptide analog of ghrelin, a hormone produced in the stomach that stimulates gastrointestinal activity. Derived from the natural ghrelin sequence, RM-131 has been optimized to stimulate gastrointestinal motility, with greater potency, and enhanced stability and pharmacokinetics.

About Gastroparesis

Gastroparesis affects a significant number of the 24 million diabetics in the U.S., with a prevalence of delayed gastric emptying of up to 30% among type 1 and type 2 diabetics. Gastroparesis symptoms include chronic nausea, vomiting, malnutrition, and results in a significant rate of hospitalization. This condition also often undermines measures to manage hyperglycemia.

About Rhythm (www.rhythmtx.com)

Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm is developing the ghrelin peptide agonist, RM-131, for the treatment of diabetic gastroparesis and other GI functional disorders, and the MC4R peptide agonist, RM-493, for obesity and diabetes. Rhythm investors include MPM Capital, New Enterprise Associates, and Third Rock Ventures. The company is based in Boston, Massachusetts.

Contact:
Bart Henderson
President
(857) 264-4281
bhenderson@rhythmtx.com <mailto:bhenderson@rhythmtx.com>

 


'/>"/>
SOURCE Rhythm
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
2. Guam rhino beetles got rhythm
3. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
4. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
5. Biosense Webster Reinforces its Leadership Position in the Electrophysiology Market at Heart Rhythm 2010
6. Rhythms RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
7. Dangerous arrhythmia analyzed in a heartbeat
8. Differing structures underlie differing brain rhythms in healthy and ill
9. Rhythm Names Keith M. Gottesdiener Chief Executive Officer
10. Rhythm Names Lex Van der Ploeg Chief Scientific Officer
11. Rap music powers rhythmic action of medical sensor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... PA (PRWEB) , ... May 02, 2016 , ... ... proud to report on the pre-launch success of their revolutionary, veterinarian-designed product for ... cats to stalk, trap, and play with their food the way nature intended. ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design team has won ... explored how bacterial properties can be applied to fabric and formed into living interfaces ... in response to humidity change. The team harvested Natto cells and applied them to ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... medicine, is excited to announce the launch of the Proove Health Foundation ... volunteerism, and education to promote the use of personalized medicine for tackling the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., ... surgical procedures, today announced the completion of a significant transaction and partnership that ... future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):